drugset / Trial / NCT04032158
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
Phase 3
Terminated
3 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
Timeline
- Start
- 2019-08-26
- Primary completion
- 2020-04-16
- Completion
- 2020-04-16
Outcome
Outcome not reported
Stopped: “Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0073. Consequently, this trial terminated early.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evobrutinib | Small molecule | — | Oral |
| Subject | Interferon beta-1a | Protein / enzyme biologic | — | Intramuscular |